Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma
References
Additional references
Asthma UK. Asthma Facts and FAQs. http://www.asthma.org.uk/asthma‐facts‐and‐statistics (accessed 20 August 2014).
Barnes PJ, Jonsson B, Klim JB. The costs of asthma. European Respiratory Journal 1996;9:636‐42. [DOI: 10.1183/09031936.96.09040636]
Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. GRADE Working Group, 2008.
British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/ (accessed 29 July 2014).
Centers for Disease Control and Prevention. Asthma Surveillance Data. http://www.cdc.gov/asthma/ (accessed 20 August 2014).
Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD009611.pub3]
Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5]
Department of Health. An Outcomes Strategy for COPD and Asthma: NHS Companion Document. https://www.gov.uk/government/publications/an‐outcomes‐strategy‐for‐copd‐and‐asthma‐nhs‐companion‐document (accessed 20 August 2014).
Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2]
Boehringer Ingelheim Limited. Summary of product characteristics: Spiriva 18 microgram inhalation powder, hard capsule. https://www.medicines.org.uk/emc/medicine/10039 (accessed 20 August 2014).
Boehringer Ingelheim Limited. Summary of product characteristics: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/medicine/20134 (accessed 20 August 2014).
Electronic Medicines Compendium. License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014).
Almirall Limited. Sumary of product characteristics: Eklira Genuair 322 micrograms inhalation powder. https://www.medicines.org.uk/emc/medicine/27001 (accessed 20 August 2014).
Global Initiative for Asthma. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 28 July 2014).
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention—Revised 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 20 October 2014). [http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf]
International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. http://www.theunion.org/what‐we‐do/publications/english/global_asthma_report2011.pdf (accessed 4 August 2014).
Masoli M, Fabian D, Holt S, Beasley R. Global Burden of Asthma. Global Initiative for Asthma. http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf (accessed 16 September 2014).
Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respiratory Research 2006;7(1):73. [DOI: 10.1186/1465‐9921‐7‐73]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org.
Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3]
National Institute of Health and Care Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care CG101. http://www.nice.org.uk/guidance/CG101 (accessed 20 August 2014).
Peters S, Kunselman S, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine 2010;363:1715‐26. [DOI: 10.1056/NEJMoa1008770]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Vogelberg C, Engel M, Moroni‐Zentgraf P, Leonaviciute‐Klimantaviciene M, Sigmund R, Downie J, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose‐ranging study. Respiratory Medicine 2014 July 17 [Epub ahead of print]. [DOI: 10.1016/j.rmed.2014.06.011]
World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva, Switzerland: World Health Organization, 2007.
